HRMY Harmony Biosciences Holdings, Inc.

NEUTRAL Impact: 3/10 144
Horizon days Filed Jun 5, 2026 Processed 9d 12h ago SEC 0001950047-26-005696
Form 144 — notice of proposed sale of securities

Price Chart

Loading chart...

Executive Summary

Former officer Sandip Kapadia filed a Form 144 notice of intent to sell 2,101 shares of Harmony Biosciences (HRMY) with an estimated aggregate market value of approximately $69,504. The shares are to be sold through Morgan Stanley Smith Barney and were acquired via exercise of options under a registered plan. This is a relatively small sale relative to Kapadia's prior reported holdings and the company's $1.9B market cap, but as a former officer filing an intent to sell, it warrants monitoring.

Actionable Insight

The sale is small in absolute and relative terms, but the pattern of recent sales by a former officer (7,064 shares on June 4 and 45,481 shares on May 8) suggests ongoing portfolio liquidation. Monitor for additional Form 4 filings or a larger Form 144 that could signal a more significant divestment. No immediate price impact expected.

Key Facts

  • Form 144 filed by Sandip Kapadia, a former officer of Harmony Biosciences Holdings, Inc.
  • Proposed sale of 2,101 shares of common stock with an estimated aggregate market value of $69,504.02.
  • Shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Shares acquired via exercise of options under a registered plan on June 5, 2026.
  • Kapadia previously sold 7,064 shares on June 4, 2026, and 45,481 shares on May 8, 2026.
  • The filing is an advance notice of intent to sell; the sale may not be completed.

Financial Impact

Proposed sale of 2,101 shares valued at approximately $69,504, representing a small fraction of the company's $1.9B market cap.

dilutioninsider selling

Risk Factors

  • Insider selling by a former officer may signal lack of confidence or personal liquidity needs, though the amount is small.
  • The filing is an intent to sell; the actual sale may not occur, reducing the signal value.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
65% bullish (17 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005696
Document: 0001950047-26-005696-index.html0001950047-26-005696
Document: 0001950047-26-005696.txt0001950047-26-005696
7 reports for HRMY
Performance horizon
Filters
Rows
Reports for HRMY — sortable, filterable
Type Now
Jun 9, 2026
5d ago
144
NEUTRAL ★ 3/10
$34.12 awaiting T+5awaiting T+5$34.46 (+1.00%)
Jun 5, 2026
9d ago
144
NEUTRAL ★ 3/10
$33.00 awaiting T+5awaiting T+5$34.46 (+4.42%)
May 19, 2026
27d ago
3
NEUTRAL ★ 5/10
$30.44 $30.76▲ +1.05%▼ −1.25%$34.46 (+13.21%)
May 7, 2026
5w ago
8-K
MIXED ★ 5/10
$31.42 $30.83▼ −1.88%▼ −3.38%$34.46 (+9.68%)
Apr 14, 2026
8w ago
8-K
MIXED ★ 6/10
$29.29 $32.14▲ +9.73%▲ +8.34%$34.46 (+17.65%)
Apr 3, 2026
10w ago
DEFA14A
NEUTRAL ★ 3/10
$27.71 $29.05▲ +4.84%▲ +0.70%$34.46 (+24.36%)
Apr 2, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$27.74 $28.89▲ +4.15%▲ +0.53%$34.46 (+24.22%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 4h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access